Hikma stock gains on epinephrine nasal spray regulatory filings

Published on 09/11/2026 at 12:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock trades higher on September 11, 2026 after the company advanced regulatory filings for its investigational epinephrine nasal spray in several markets. Recent half-year figures show growing revenue and profitability that underpin the move.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma Pharmaceuticals stock (ISIN GB00B128J450) is trading higher on September 11, 2026 after the company advanced multi-market regulatory filings for its investigational epinephrine nasal spray, a step that investors see as strengthening its specialty portfolio.

Regulatory filings support growth story

According to RTTNews on September 11, 2026, Hikma has submitted regulatory filings for its epinephrine nasal spray in multiple markets, while the product remains investigational and is not yet approved by the US Food and Drug Administration.

As RTTNews reports, Hikma’s US-traded American depositary receipt HKMPY has moved within a 52-week range between USD 31.80 and USD 50.56 and closed the prior trading session at USD 41.31, placing the shares about 30.8 percent above the low but still roughly 18.4 percent below the high over that period.

Recent financial performance and fundamentals

Hikma’s latest reported figures show that over the trailing twelve months the group generated revenue of USD 3.42 billion, providing the scale to support continued investment in product development and regulatory work, according to data from Yahoo Finance.

Over the same trailing period, Hikma recorded net income attributable to common shareholders of USD 387 million and a profit margin of 11.32 percent, illustrating a profitable business model that can absorb the costs of bringing new emergency medicine products such as the epinephrine nasal spray to market, as shown by Yahoo Finance.

Balance sheet figures indicate total cash of USD 289 million and a total debt-to-equity ratio of 77.11 percent, which investors will monitor closely as Hikma advances multiple regulatory submissions in parallel, according to Yahoo Finance.

Stock performance and investor perspective

On its primary listing on the London Stock Exchange, Hikma Pharmaceuticals PLC trades under the ticker HIK.L, with the shares quoted at GBP 1,511.00 as of September 11, 2026 during market hours, up about 0.87 percent from the previous close of GBP 1,498.00, based on data from Yahoo Finance.

The current level compares with an indicated average price of around GBP 1,704.58 and a 52-week high of GBP 2,617.19, meaning the stock is trading meaningfully below its recent peak even after a year-to-date total return of 2.47 percent that still lags the FTSE 100 index’s 7.29 percent over the same period, according to Yahoo Finance.

For income-oriented investors, Hikma offers a forward annual dividend of GBP 0.64 per share, corresponding to a forward dividend yield of 4.19 percent at recent prices, which provides a cash return while the market waits to see how the epinephrine nasal spray progresses through the regulatory process, as reported by Yahoo Finance.